INCYHealthcare · BiotechnologyThe 28 Wall Street analysts covering Incyte Corp. hold a median 12-month price target of $129 — +14.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 8 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Incyte Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (100): The share price has been relatively steady.
Revisions (44): Analysts have, on balance, been cutting their forecasts.
Size (9): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on INCY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +14.4% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Oct 2026 | Stifel | Maintains | Buy | $145 → $157 |
| 1 Oct 2026 | Wells Fargo | Maintains | Equal-Weight | $116 → $128 |
| 28 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $150 → $152 |
| 28 Sept 2026 | JP Morgan | Maintains | Neutral | $120 → $123 |
| 22 Sept 2026 | RBC Capital | Reiterates | Sector Perform | — |
| 22 Sept 2026 | RBC Capital | Reiterates | Sector Perform | $109 |
| 20 Aug 2026 | Canaccord Genuity | Initiates | Buy | $152 |
| 20 Aug 2026 | Canaccord Genuity | Initiates | Buy | — |
| 20 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $150 |
| 17 Aug 2026 | Piper Sandler | Maintains | Overweight | — |
| 17 Aug 2026 | Piper Sandler | Maintains | Overweight | $110 → $130 |
| 4 Aug 2026 | Mizuho | Maintains | Outperform | — |
| 4 Aug 2026 | Mizuho | Maintains | Outperform | $121 → $137 |
| 3 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $150 |
| 3 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Aug 2026 | Leerink Partners | Maintains | Outperform | $131 → $155 |
| 3 Aug 2026 | Leerink Partners | Maintains | Outperform | — |
| 29 July 2026 | Barclays | Maintains | Overweight | — |
| 29 July 2026 | Barclays | Maintains | Overweight | $134 → $139 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INCY appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Incyte Corp. returned +32.1% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 47% of US stocks
Cheaper than 31% of US stocks
Cheaper than 27% of US stocks
Cheaper than 39% of US stocks
Higher than 82% of US stocks
Higher than 73% of US stocks
Higher than 98% of US stocks
Higher than 93% of US stocks
Higher than 87% of US stocks
Higher than 88% of US stocks
Higher than 98% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Incyte Corp. has a market value of $22.9B and an enterprise value of $18.4B.
Revenue in the twelve months to 30 June 2026: $5.8B. The latest quarter grew 37.7% year on year.
Net income over the same four quarters: $1.6B, a 27.7% net margin.
Diluted earnings per share, trailing twelve months: $7.85.
Free cash flow in the twelve months to 30 June 2026: $1.9B, after $59.2M of capital spending.
Trailing P/E: 14.4×; forward P/E: 12.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Incyte Corp. employs 2,844 people — $2.0M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Incyte Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Incyte announced that it will report its third-quarter 2026 financial results.
Why it matters — The announcement signals an upcoming update on Incyte’s financial results for investors following INCY.
Knight Therapeutics announced expedited ANVISA approval in Brazil for NIKTIMVO® (axatilimab) to treat chronic graft-versus-host disease in eligible adult and pediatric patients after at least two prior systemic therapies.
Why it matters — The approval concerns a treatment for chronic graft-versus-host disease, a relevant therapeutic area for Incyte watchers.
Zacks Investment Research published a piece comparing Incyte (INCY) and Techne (TECH) to assess which of the two Medical - Biomedical and Genetics stocks is more attractive to value investors. The article poses the question of which stock is the better value pick.
Why it matters — INCY watchers would care because this comparative value analysis frames how the company is positioned against a peer within the biomedical and genetics sector.
Mirum Pharmaceuticals has received FDA approval for Atebrioz, a treatment for the ultra-rare bone disorder fibrodysplasia ossificans progressiva (FOP), based on PROGRESS data showing a reduction in new heterotopic ossification lesion volume.
Why it matters — INCY watchers may monitor this competitive development in the ultra-rare disease space as a reference point for peers and market dynamics in rare-disease therapies.
MiniMed announced that Sheila Denton has been appointed General Counsel & Corporate Secretary. The company, a diabetes-technology leader trading on Nasdaq, made the announcement on Sept. 28, 2026.
Why it matters — The appointment is an internal corporate governance matter at MiniMed with no direct bearing on Incyte Corp., so INCY watchers would find it immaterial to their holdings.
The 28 Wall Street analysts covering Incyte Corp. have a median 12-month price target of $129, with estimates ranging from $86 to $157. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 28 analysts covering Incyte Corp., 12 rate it a Buy, 15 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Incyte Corp. 89 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Incyte Corp. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).
No one can know that. What the data says: the median 12-month target from 28 analysts implies +14.4% from the last close, and Ticker Nerd's factor model ranks Incyte Corp. 89 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Incyte Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INCY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $86 to $157 over the next 12 months.
Incyte Corp. returned +32.1% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Incyte Corp. is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics.
The most recent item we track (Business Wire, 8 Oct 2026): "Incyte to Report Third Quarter Financial Results". Incyte announced that it will report its third-quarter 2026 financial results.
Incyte Corp. is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company’s current portfolio centers on hematology, oncology, and inflammation and autoimmunity, with products and programs aimed at treating cancers, blood disorders, and immune-mediated conditions. Incyte Corp. develops both small-molecule medicines and biologics, and its marketed therapies support patients with a range of specialty disease areas, including dermatology and rare hematologic disorders. The company also maintains a pipeline of clinical-stage candidates across its core therapeutic franchises, reflecting its role as a research-driven developer of targeted treatments. Headquartered in Wilmington, Delaware, Incyte Corp. serves healthcare markets in the United States and internationally through its commercial and development activities.
CEO Mr. William J. Meury · 2,844 employees · United States · https://www.incyte.com
